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Summary
 
Two major mechanisms for the regulation of autoreactive B cells that arise in the bone marrow
are functional silencing (anergy) and deletion. Studies to date suggest that low avidity interac-
tions between B cells and autoantigen lead to B cell silencing, whereas high avidity interactions
lead to deletion. Anti–double stranded (ds) DNA antibodies represent a pathogenic autospeci-
ficity in Systemic Lupus Erythematosus (SLE). An understanding of their regulation is critical
to an understanding of SLE. We now demonstrate in a transgenic model in which mice express
the heavy chain of a potentially pathogenic anti-DNA antibody that antibody affinity for ds-
DNA does not alone determine the fate of anti-dsDNA B cells. B cells making antibodies with
similar affinities for dsDNA are regulated differently, depending on light chain usage. A major
implication of this observation is that dsDNA may not be the self antigen responsible for cell
fate determinations of anti-dsDNA B cells. Light chain usage may determine antigenic cross-
reactivity, and cross-reactive antigens may regulate B cells that also bind dsDNA.
 
A
 
nti–double stranded (ds)
 
1
 
 DNA antibodies are charac-
teristic of the autoimmune disease SLE and titers of
IgG anti-dsDNA antibodies in patients’ serum correlate with
disease activity and nephritis. Analyses of the immunoglob-
ulin variable region gene loci reveal no differences between
autoimmune and nonautoimmune mouse strains and no
differences in human kindreds that associate with autoim-
mune disease. Furthermore, the immunoglobulin variable
region (V) genes used in both murine and human anti-
DNA antibodies are also used in the generation of a protec-
tive antibody repertoire (1–5).
Studies of the regulation of autoreactive B cells became
possible with the advent of transgenic technology. Analyses
of B cells expressing transgene encoded autoantibodies have
demonstrated the existence of several mechanisms for main-
taining self tolerance: functional silencing or anergy, dele-
tion, and receptor editing (6–13). Based on investigations
from several laboratories, Goodnow has proposed that there
are thresholds of receptor occupancy that correlate with
different mechanisms of regulation (14). According to this
model, deletion occurs under conditions of extensive re-
ceptor cross-linking, whereas silencing occurs under condi-
tions of more moderate cross-linking.
To study the regulation of anti-dsDNA antibodies, we
previously generated nonautoimmune BALB/c and NZW
mice transgenic for the 
 
g
 
2b heavy chain of the R4A anti-
dsDNA antibody. The R4A antibody is encoded by an S107
V11 heavy chain gene and a Vk1 light chain gene, binds
dsDNA, and deposits in glomeruli of SCID mice (15, 16). In
R4A-
 
g
 
2b transgenic BALB/c and NZW mice, negligible
anti-DNA activity is present in the serum, and fusion of un-
stimulated splenocytes from these mice fails to yield transgene
expressing anti-dsDNA hybridomas. Anti-dsDNA B cells,
however, are present in the spleens of these mice and can
be activated in vitro by LPS to secrete transgene encoded
anti-dsDNA antibody. Furthermore, R4A anti-dsDNA
hybridomas can be obtained from these mice if splenocytes
are stimulated in vitro with LPS before fusion (9, 17).
In the present study we compared transgene expression
in nonautoimmune BALB/c and NZW mice and autoim-
mune NZB/W F1 mice. While negligible transgene-encoded
anti-DNA activity is present in the serum of BALB/c and
NZW mice, such activity is present in the serum of all
NZB/W F1 mice. Analyses of hybridomas show that trans-
gene expressing anti-dsDNA B cells from NZB/W F1
mice use a broad spectrum of light chain genes. In contrast,
anti-dsDNA B cells from nonautoimmune mice use almost
exclusively Vk1 genes. Thus, two populations of anti-
dsDNA B cells exist, which are differentially regulated in
nonautoimmune mice. There is a Vk1 anti-dsDNA subset
that is present but is functionally silent, and a non-Vk1 sub-
set which is targeted for deletion. In the NZB/W F1 au-
toimmune background, both populations are activated in
vivo. Since the Vk1 and the non-Vk1 anti-dsDNA anti-
 
1
 
Abbreviations used in this paper:
 
 ds, double-stranded; FR1, framework 1; ss,
single-stranded; V, variable region.
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bodies have similar affinities for dsDNA, this critical, po-
tentially pathogenic, specificity cannot be regulated solely
by binding to dsDNA. Alternative models of regulation in
which cell fate is determined by light chain usage need to
be considered.
 
Materials and Methods
 
Transgenic Mice.
 
Mice expressing the R4A-
 
g
 
2b heavy chain
transgene have been previously reported (9, 17). Transgene ex-
pressing NZB/W F1 mice were generated by breeding transgenic
NZW mice with wild-type NZB mice.
 
Generation of Hybridomas.
 
Spleens cells derived from two 8-wk-
old unimmunized transgenic NZW mice and two unimmunized
transgenic BALB/c mice were fused after stimulation for 48 h in
vitro with LPS (17).
Six fusions were performed using spleen cells from eight
NZB/W F1 transgenic mice ranging in age from 2.5–10 mo.
Three fusions were performed with naive spleen cells; two were
performed with LPS stimulated cells. In one fusion, half of the
splenocytes were stimulated with LPS for 48 h before fusion and
the other half were fused without prior exposure to LPS. Hybri-
domas were screened by ELISA for 
 
g
 
2b dsDNA binding as previ-
ously described (17). Cells from hybridoma wells displaying anti-
dsDNA activity were cloned in soft agar.
 
Analysis of V Gene Expression.
 
Hybridoma clones were screened
for expression of R4A-
 
g
 
2b and Vk1 genes by RNA dot blot using
probes specific for the mouse S107 and Vk1 gene families as pre-
viously described (17). A Vk1 probe was provided by Dr. C.
Schildkraut (Albert Einstein College of Medicine, Bronx, New
York; reference 18).
Total RNA was isolated from hybridomas (Ultraspec RNA
kit; Biotecx Labs., Houston, TX). First strand cDNA for the R4A
heavy chain and 
 
k
 
 light chain genes were synthesized using 10 
 
m
 
g
of RNA and 100 ng of antisense oligonucleotide primers specific
for the mouse gamma constant region (TGGACAGGGA/CTC-
CAG/TAGTTC) and for the mouse 
 
k
 
 light chain constant re-
gion (ACACTCATTCCTGTTGAA). PCR amplification was
performed using vent polymerase. For the R4A heavy chain gene,
an oligomer specific for framework 1 (FR1; GGTGAAGCTG-
GTGGAATCTGG) and the gamma constant region primer were
used; for kappa light chain genes a Vk1, FR1-specific oligomer
(CCAGCAGTGATGTTGTGATGACCC) or a cocktail of de-
generate FR1, Vk oligomers (19), and the 
 
k
 
 constant region
primer were used. PCR products were sequenced with the ds-
DNA cycle sequencing system (GIBCO BRL, Gaithersburg,
MD) using constant region, FR1, and internal primers. Sequenc-
ing reactions were electrophoresed on 6 or 7% acrylamide gels.
 
Allelic Exclusion.
 
Allelic exclusion of anti-dsDNA hybridomas
was determined by ELISA as previously described (17). In brief,
96-well Falcon plates (Becton Dickinson, Lincoln Park, NJ) were
coated with a 1/1,000 dilution of goat anti–mouse antibody to
IgM, IgG1, IgG3, IgG2a, or IgG2b (Southern Biotechnology
Assoc., Birmingham, AL). After blocking plates in PBS, 1.0%
BSA, cell supernatants normalized to 10 
 
m
 
g/ml were added to
wells for 1 h at 37
 
8
 
C followed by the addition of goat anti–mouse
IgM, IgG1, IgG3, IgG2a, or IgG2b antibody, respectively, conju-
gated to alkaline phosphatase (Southern Biotechnology Assoc.).
All ELISA washes were performed with PBS–0.05% Tween.
ELISAs were developed with 
 
p
 
-nitrophenylphosphate disodium
as substrate (Sigma Chemical Co., St. Louis, MO) and ELISAs
were read at 405 nm in a Titertek-Multiscan ELISA reader.
 
Antibody Quantitation.
 
IgG2b antibodies in hybridoma super-
natants were quantitated by ELISA as previously described (16).
 
Analysis of Antigenic Specificity.
 
Quantitated hybridoma super-
natants were tested by ELISA for binding to dsDNA and single
stranded (ss) DNA. The dsDNA ELISA was performed on sal-
mon sperm DNA–coated Immulon 2 ELISA plates (Dynatech
Labs. Inc., Chantilly, VA) according to Iliev et al. (17). The ss-
DNA ELISA was performed as described for dsDNA (17) except
that salmon sperm DNA was not filtered through a nitrocellulose
filter and was denatured by boiling and quick cooled on ice be-
fore coating Immulon 2 plates.
 
Affinity Measurements of Anti-dsDNA Antibodies.
 
Affinity con-
stants for selected anti-dsDNA antibodies were determined ac-
cording to an antigen inhibition ELISA as described by Nieto et al.
(20). Immulon 2 plates were coated with 100 
 
m
 
g/ml salmon
sperm DNA and blocked in PBS, 1.0% BSA. Hybridoma super-
natants diluted to an antibody concentration that was within the
linear range on an anti-dsDNA antibody titration curve, were then
incubated in wells of ELISA plates along with increasing concen-
trations of soluble salmon sperm DNA used as inhibitor (0.0–2
mg/ml) for 2 h at 37
 
8
 
C. Wells were washed and incubated for 1 h
at 37
 
8
 
C with goat anti–mouse IgG2b conjugated to alkaline phos-
phatase and developed with substrate solution as described above.
ELISA measurements were read at 405 nm in a Titertek Multi-
scan ELISA reader. Apparent affinities were calculated based on
the concentration of soluble DNA resulting in 50% inhibition of
antibody binding (20).
Dissociation constants were determined according to the
method of Friguet et al. (21). In brief, linearized plasmid DNA
was nick translated with 
 
32
 
P-labeled deoxynucleotide triphosphates.
A constant amount of antibody was combined with various
amounts of radiolabeled DNA (5–100 ng), brought to a final vol-
ume of 1.0 ml with SSC, and then incubated for 3 h at room
temperature. Antibody–dsDNA complexes were trapped on 0.45
 
m
 
m type HA millipore filters (Millipore Corp., Bedford, MA).
Bound radioactivity was detected on a liquid scintillation counter.
Results were plotted and dissociation constants were obtained
from the slope of the linear regression.
 
Pathogenicity of Anti-dsDNA Antibodies.
 
Hybridoma cells (5 
 
3
 
10
 
6
 
) from two lines, BW7E6H1 and NZW14E10, were injected
intraperitoneally into pristane-primed SCID mice. 3 wk after in-
jections, animals were killed, and kidneys removed and imbedded
in paraffin. Sections were stained with biotin-conjugated goat
anti–mouse IgG (Vectastain ABC kit; Vector Labs., Inc., Burlin-
game, CA) and then developed with NBT-BCIP substrate
(GIBCO BRL) according to Katz et al. (16). Stained sections
were viewed with a Zeiss microscope.
 
Results
 
Generation of Hybridomas from Nonautoimmune Mice.
 
While splenocytes from nonautoimmune NZW and
BALB/c R4A-
 
g
 
2b transgenic mice can be induced to se-
crete transgene encoded anti-dsDNA antibodies by in vitro
stimulation with LPS, spontaneous secretion of 
 
g
 
2b anti-
dsDNA antibody is negligible in these mice (9). In contrast,
NZB/W F1 R4A-
 
g
 
2b transgenic mice have elevated titers
of 
 
g
 
2b anti-dsDNA. These antibodies are transgene en-
coded; at 2.5–3 mo of age, elevated titers of 
 
g
 
2b DNA
binding activity is present only in the sera of transgenic
NZB/W F1 mice and not in nontransgenic littermates (Fig. 1).
To understand the differential regulation of anti-dsDNA 
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B cells in autoimmune and nonautoimmune mice, we gen-
erated transgene encoded anti-dsDNA hybridomas. We
were able to obtain anti-dsDNA producing hybridomas from
NZW or BALB/c mice only if splenocytes were cultured
with LPS before fusion (17). 5–10% of hybridomas from
LPS-stimulated splenocytes expressing the R4A-
 
g
 
2b trans-
gene bound dsDNA. 20 anti-dsDNA hybridomas, 9 from
NZW mice, and 11 from BALB/c mice, were analyzed in de-
tail. Expression of the transgene was verified in these clones
by sequencing through the VDJ junction of the 
 
g
 
2b heavy
chain in all hybridomas and throughout the entire V region
in half. Sequence analysis revealed the heavy chain to be
encoded by the transgene in all cases and further revealed
that there was no somatic mutation of the R4A heavy chain.
To examine the endogenous light chains expressed in
these hybridomas, we first looked for expression of a Vk1
transcript by RNA dot blot since the “wild-type” R4A an-
tibody possesses a Vk1 light chain (15). 17 of 20 lines ex-
pressed a Vk1 light chain. All light chains were sequenced
(Fig. 2) confirming the light chain identification obtained
by RNA dot blot. The Vk1-A gene was used in the major-
ity (12) of hybridomas. 16 of the Vk1 light chain genes
were somatically mutated. The three non-Vk1 anti-dsDNA
associated light chains, BA12BB2, BA12BD-1, and BA1227,
were derived from BALB/c hybridomas and are encoded by
Vk21, Vk2, and Vk4/5 genes respectively (data not shown).
 
Generation of Hybridomas from NZB/W F1 Autoimmune
Mice.
 
Transgene expressing anti-dsDNA hybridomas
from R4A-
 
g
 
2b transgenic NZB/W F1 mice could be ob-
tained from non-LPS activated B cells as well as from LPS
activated splenocytes, confirming activation in vivo of anti-
dsDNA B cells in the autoimmune mice. In contrast to the
dominant Vk1 usage seen in nonautoimmune mice, only 5
of 16 autoimmune derived anti-dsDNA hybridomas use a
Vk1 gene (Table 1). 12 cell lines were obtained from LPS-
stimulated splenocytes, of which only 4 (33%) use Vk1
genes. Only 1 of 4 cell lines obtained from unstimulated
NZB/W F1 splenocytes (25%) uses a Vk1 light chain. There-
fore, there is little difference in the frequency of Vk1 ex-
pression in hybridomas from LPS-stimulated and unstimu-
lated splenocytes. Vk1 genes from NZB/W F1 hybridomas
display no somatic mutation in three (BW19G10, BW21D11,
and BW10D9) of the five Vk1 genes sequenced (Fig. 3).
The base change observed at the junction of Vk and Jk in
Bw19G10 and BW21D11 is likely the result of imprecise
joining during Vk-Jk rearrangement.
The remaining 11 hybridomas use light chains from
eight different non-Vk1 light chain gene families (Fig. 4),
including two from the Vk10 family and three from the
Vk4/5 family. Since none of the non-Vk1 genes share
100% homology with any germline genes reported in the
EMBL/GenBank/DDBJ database, we cannot determine
whether they are somatically mutated or whether they rep-
resent novel germline genes.
We previously observed that R4A anti-dsDNA hybrido-
mas from nonautoimmune mice display a lack of allelic ex-
clusion, whereas the transgene expressing non-dsDNA
binding hybridomas all display intact allelic exclusion (17).
We, therefore, examined the R4A anti-dsDNA hybrido-
mas from NZB/W F1 mice for expression of endogenous 
 
m
 
,
 
g
 
1, 
 
g
 
3, or 
 
g
 
2a heavy chain. Hybridoma supernatants were
assayed by ELISA for binding to anti-isotype antibodies.
Most hybridomas (14 of 16) were observed to express en-
dogenous heavy chain as well as the R4A-
 
g
 
2b heavy chain.
In nine hybridomas, the endogenous heavy chain is of the
 
m
 
 isotype; in 5, it is of the 
 
g
 
3 or 
 
g
 
2a isotype. All hybrido-
mas failing to display allelic exclusion demonstrated expres-
sion of a second isotype as detected by an OD reading that
was at least fivefold above background levels (OD
 
405
 
 
 
nm
 
.
 
0.6). Two hybridomas from NZB/W F1 mice, BW10D9
and BW7E6, demonstrated no binding above background
to anti-
 
m
 
, 
 
g
 
1, 
 
g
 
3, or 
 
g
 
2a (OD
 
405
 
 
 
nm
 
 
 
,
 
0.150) suggesting that
they maintained allelic exclusion or that they secreted an
endogenous 
 
g
 
2b heavy chain.
 
Comparison of Vk1 and Non-Vk1 Anti-DNA Antibodies.
 
Comparison of the light chain repertoire of transgene-
encoded anti-dsDNA antibodies used by the nonautoimmune
and autoimmune mice (Table 1) demonstrates a statistically
significant dominance of Vk1 light chains in hybridomas
from the nonautoimmune BALB/c and NZW mice. To
understand how R4A-Vk1 anti-DNA antibodies might dif-
fer from R4A non-Vk1 anti-DNA antibodies, we compared
Figure 1. Measurement of R4A-g2b anti-dsDNA antibody in the sera
of NZB/W F1 transgenic and non transgenic mice. Sera from 10 trans-
genic (Tg1) NZB/W F1 mice and 10 nontransgenic (Tg2) littermates
were diluted 1⁄500 and then tested by ELISA for binding of g2b antibody
to dsDNA. Ages of Tg1 and Tg2 mice range from 10–21 wk. There is
no linear relationship between age of the mouse and anti-dsDNA titer
within these populations. *Mean value significantly exceeds mean value
for Tg2 mice. P ,0.002 (Student’s t test). 
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binding to dsDNA by ELISA (Fig. 5). A similar spectrum
of binding was present among antibodies with both Vk1
and non-Vk1 light chains. Several non-Vk1 antibodies dis-
played lower dsDNA binding than Vk1 antibodies, dem-
onstrating that the non-Vk1 antibodies did not represent a
higher affinity subset. We also measured the apparent affin-
ity of some representative Vk1 and non-Vk1 anti-dsDNA
antibodies in a DNA inhibition assay (20). There was no
difference in the range of affinities among the Vk1 and the
non-Vk1 anti-dsDNA antibodies (Table 2). One antibody
Figure 2. Nucleotide and amino acid sequences of Vk1 light chains
from nonautoimmune transgenic hybridomas. Light chain nucleotide and
amino acid sequences from hybridomas from nonautoimmune BALB/c
and NZW transgenic mice are compared to their most homologous Vk1
germline genes. (A) Vk1-A; (B) 36.1.2D, an atypical Vk1-a (1–6) dextran
germline gene; and (C) Vk1-C (38–40). CDR regions are underlined and
are according to Kabat et al. (40). Dashes indicate identity of nucleotides
to the germline sequence. Silent base changes are designated by lowercase
letters. Nucleotide changes leading to amino acid replacements in the V
region are indicated by uppercase letters. Those leading to amino acid re-
placements in the joining (J) regions are indicated in bold uppercase let-
ters. Amino acid replacements are shown above the nucleotide sequence.
Amino acid replacements from the germline J are indicated in bold. Light
chains derived from BALB/c mice have the prefix BA preceding the nu-
meric designation. Light chains derived from NZW mice have the prefix
NZW preceding the numeric designation. 
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which binds only moderately well to dsDNA-coated plates
(BW16B2) by direct ELISA, appears to have a higher ap-
parent affinity, as detected by a DNA inhibition ELISA,
than expected. This antibody may bind better to DNA in
solution than to DNA in a solid phase, a characteristic of
some anti-DNA antibodies which has previously been ob-
served (22).
Because it has been reported that B cells with specificity
for ssDNA are tolerized by anergy induction, while B cells
binding dsDNA are deleted (8), we assayed for cross-reac-
tivity with ssDNA by ELISA (Table 3). At 2 
 
m
 
g/ml, one Vk1
anti-dsDNA antibody, BA129B-1, derived from a BALB/c
mouse, and two non-Vk1 anti-dsDNA antibodies, BW14C7B1
and BW9B5F7, derived from an NZB/W F1 mouse bind
strongly to ssDNA (Table 3) relative to R4A. Two other
anti-dsDNA antibodies, one from a BALB/c mouse and
one from an NZB/W F1 mouse, show less than a twofold
increase in binding ssDNA relative to R4A. The remainder
of the anti-dsDNA antibodies from both autoimmune and
nonautoimmune mice display binding to ssDNA less than
twofold greater than the binding of R4A.
To test for pathogenicity, a Vk1-expressing cell line,
NZW145-D2, derived from an NZW transgenic mouse,
and a non-Vk1 expressing line, BW7E6H1, derived from
an NZB/W F1 transgenic mouse, were injected into SCID
mice. NZW145D-2 and BW7E6H1 were selected for
pathogenicity studies because both cell lines are allelically
excluded and secrete only the transgenic antibody. Further-
more, antibodies from both hybridomas have similar bind-
ing characteristics. They both bind moderately well to ds-
DNA by ELISA (Fig. 5) and both have dissociation
constants in the range of 10
 
2
 
9
 
–10
 
2
 
8
 
 as detected by a filter
binding assay (21). After 3 wk, kidneys were removed from
these mice and stained for antibody deposition. In both
cases, deposition of IgG was observed in glomeruli (Fig. 6,
 
B
 
 and 
 
C
 
) suggesting that both Vk1 and non-Vk1 R4A
anti-dsDNA antibodies have pathogenic potential.
 
Discussion
 
Anti-dsDNA antibodies represent a major pathogenic
specificity in SLE. To understand their regulation in non-
autoimmune and autoimmune hosts, we generated mice
expressing the heavy chain of an IgG2b pathogenic anti-
dsDNA antibody. This heavy chain, expressed in associa-
tion with an endogenous light chain repertoire, can form
antibodies with a variety of affinities for dsDNA. The anal-
ysis of serum and hybridomas from R4A transgenic mice
leads to several important observations.
The first observation is that there is a defect in tolerance
 
Table 1.
 
Vk Gene Usage
 
Strains Total No. Vk1 (%) Non-Vk1 (%)
BALB/c 11 8 (73) 3 (27)
NZW 9 9 (100) 0 (0)
NZB/W F1 16 5 (31)
 
*
 
11 (69)
LPS stimulated 12 4 (33) 8 (66)
Unstimulated 4 1 (25) 3 (75)
 
*
 
Significantly less than NZW (
 
P
 
 
 
,
 
0.002) and BALB/c (
 
P
 
 
 
,
 
0.05) Pear-
son 
 
x
 
2
 
 test.
Figure 3. Nucleotide and amino acid sequences of Vk1 light chains from
autoimmune transgenic hybridomas. Light chain nucleotide and amino
acid sequences from hybridomas from autoimmune NZB/W F1 trans-
genic mice are compared to their most homologous Vk1 germline genes.
(A) Vk1-A, (B) Vk1-B, and (C) Vk1-C (38, 41). CDR regions are under-
lined and are according to Kabat et al. (40). Dashes indicate identity of
nucleotides to the germline sequence. Silent base changes are designated
by lowercase letters. Nucleotide changes leading to amino acid replace-
ments in the V region are indicated by uppercase letters. Those leading to
amino acid replacements in the J regions are indicated in bold. Amino acid replacements are indicated above the nucleotide sequence. Amino acid re-
placements from the germline J are indicated in bold. The BW prefix precedes all numeric designations of light chains derived from NZB/W F1 mice.1322 Differential Regulation of Anti–double-stranded DNA B Cells
induction in transgenic NZB/W F1 mice leading to ele-
vated serum titers of transgenic g2b anti-dsDNA antibody
in this autoimmune strain. In the autoimmune MRL/lpr
mouse which has a defect in the Fas gene, Roark et al. have
similarly observed a breakdown of tolerance of transgenic
anti-dsDNA antibodies (23) and have suggested that loss of
Fas may lead to the accumulation of autoreactive B cells.
Other studies, however, have demonstrated intact regula-
tion of transgenic autoantibodies in MRL/lpr mice sug-
gesting that Fas is not essential for maintaining B cell toler-
ance (24, 25). Studies in transgenic NZB/W F1 mice may
help us determine what factors, besides decreased Fas ex-
pression, may lead to a breakdown in tolerance in autoim-
mune-prone mice.
A second observation is that the transgenic anti-dsDNA
antibodies derived from NZB/W F1 mice are often en-
coded by unmutated light chain genes. 3 out of 5 Vk1
genes are unmutated in NZB/W F1 mice compared to 1
out of 17 in BALB/c and NZW mice. Although studies of
anti-dsDNA antibodies from nontransgenic NZB/W F1
mice show the antibody genes to be somatically mutated,
little information is available on whether the mutations lead
to specificity for dsDNA or whether the autoreactivity is
germline encoded. It is possible that autoreactive B cells
whose specificities are germline encoded escape regulation
in the bone marrow and exit to the periphery where they
then acquire somatic mutations after activation by self anti-
gens. Thus, there are two possible explanations for the fact
that autoantibodies obtained from nontransgenic NZB/W
F1 mice are somatically mutated; either the mutations are
necessary for autospecificity, or the mutations occur in al-
ready autoreactive B cells that are not tolerized. Our studies
indicate that in the transgenic NZB/W F1 mice, anti-
dsDNA B cells arising in the bone marrow can move into
peripheral lymphoid organs and secrete germline encoded
autoantibody. Furthermore, B cell activation occurs with-
out molecular evidence for T cell help.
A third observation from our studies is that transgene
expressing anti-dsDNA hybridomas from both nonautoim-
mune and autoimmune strains display a lack of allelic ex-
clusion. In NZW- and BALB/c-derived hybridomas, the
majority of endogenous antibodies display no binding to
dsDNA. We had previously speculated that the endoge-
nous heavy chain is instrumental to survival of the autore-
active B cell (17). In the NZB/W F1–derived hybridomas,
however, the endogenous heavy chain may display DNA-
binding specificity (Spatz, L., V. Saenko, and B. Diamond,
unpublished observations). Therefore, the reason for the
lack of allelic exclusion in transgenic NZB/W F1 mice is
unclear. Although many anti-dsDNA B cells present in
nontransgenic NZB/W F1 mice have been shown to dis-
play intact allelic exclusion, the frequency of nonallelically
excluded autoreactive B cells has not been examined in
these mice. It has been demonstrated in B cells of MRL-
lpr/lpr mice transgenic for an anti-DNA antibody, that al-
lelic exclusion is more often absent than in B cells from
nonautoimmune transgenic strains (26). Perhaps there is an
intrinsic B cell defect in both MRL/lpr and NZB/W F1 B cells
such that the production of a transgenic heavy chain does
not effectively repress further heavy chain rearrangements.
A fourth and major observation is that anti-dsDNA anti-
bodies from the nonautoimmune mice preferentially use Vk1
light chains, whereas those obtained from autoimmune mice
Figure 4. Nucleotide and amino acid sequences of non-Vk1 light chains
from autoimmune transgenic hybridomas. Light chain nucleotide and
amino acid sequences from hybridomas from the autoimmune NZB/W
F1 transgenic mice are grouped according to families. Family assignment
is based on having .90% homology with other family members as re-
ported in EMBL/GenBank/DDBJ. CDR regions are underlined and are
according to Kabat et al. (40). Dots have been introduced in CDR1 to
maximize homology. Nucleotide changes leading to amino acid replace-
ments in the J regions are indicated in bold uppercase letters. Amino acids
are designated by uppercase letters. Replacements from the germline J re-
gion are in bold. N, represents a nucleotide that could not be resolved by
sequencing.1323 Spatz et al.
are encoded by a broad spectrum of Vk genes. This finding
suggests that autoreactive B cells expressing non-Vk1 light
chains are deleted from the nonautoimmune strains and that
light chain usage influences cell fate. Further support for
the deletion of non–Vk1-R4A B cells in nonautoimmune
mice comes from studies of BALB/c mice transgenic for
both R4A-g2b and bcl-2. These mice have transgenic anti-
DNA B cells in the spleen expressing a broad spectrum of
Vk genes (Kuo, P., and B. Diamond, unpublished observa-
tions).
Decreased Vk1 usage in NZB/W F1 mice is not due to
an abnormality in the k light chain gene locus of the NZB
mouse. Autoantibody production has been observed in
many different Igk-V haplotypes and RFLP analysis has
failed to identify particular lupus-associated Igk-V genes (27).
Previous studies suggest that the Igk-V gene loci in au-
toimmune mouse strains are normal (28) and Gavalchin et
al. have demonstrated that the V regions encoding a set of
pathogenic anti-DNA antibodies in the (NZB 3 SWR)F1
lupus-prone mice are often derived from the nonautoim-
mune SWR parental strain (1). Allelic polymorphisms exist
among individual light chain genes from different inbred
Figure 5. Binding to dsDNA.
Hybridoma supernatants from
BALB/c (BA), NZW, and
NZB/W F1 (BW) transgenic
mice were normalized to a g2b
concentration of 10 mg/ml and
assayed for binding to salmon
sperm dsDNA by ELISA. Wild-
type R4A-g2b antibody and ir-
relevant g2b are used as positive
and negative controls, respec-
tively. Shaded boxes, Vk1 anti-
bodies; open boxes, non-Vk1
antibodies. (A) Strong dsDNA-
binding  antibodies. Strong ds-
DNA binders are defined as those
whose ELISA measurements at
405 nm are at least fourfold
greater than R4A after a 4-h in-
cubation with alkaline phos-
phatase substrate solution. (B)
Moderate dsDNA-binding anti-
bodies. Moderate dsDNA bind-
ers are defined as those whose
ELISA measurements at 405 nm
range from 0.75–2-fold that of
R4A after overnight incubation
with substrate solution. Results
are the average of triplicates 6
standard deviation. Standard de-
viations ,0.010 do not appear
on the bar graph.1324 Differential Regulation of Anti–double-stranded DNA B Cells
strains. However, this cannot account for the dominant us-
age of Vk1-A light chains among anti-dsDNA antibodies
obtained from transgenic BALB/c mice and their relative
paucity among transgenic anti-dsDNA antibodies obtained
from NZB/W F1 mice because an identical Vk1-A gene is
present in both strains (29). Furthermore, it is unlikely that
the dominant expression of Vk1 genes by anti-dsDNA an-
tibodies obtained from the nonautoimmune transgenic
mice is due to biased use of Vk1 genes in cells expressing
the R4A-g2b transgene. None of the 19 randomly selected
R4A-g2b-expressing, non–DNA-binding antibodies from
NZW hybridomas express a Vk1 light chain (17). The pre-
dominant expression of Vk1 anti-dsDNA antibodies,
therefore, demonstrates that anti-DNA B cells with non-
Vk1 light chains are targeted for deletion in nonautoim-
mune strains.
To understand why Vk1-expressing B cells escape to the
periphery and persist in an unactivated, silent state, whereas
non-Vk1 B cells undergo deletion in nonautoimmune strains,
we looked for differences in binding to dsDNA that might
account for their differential regulation. While current mod-
els of B cell tolerance suggest that low avidity interactions
with antigen lead to anergy while high avidity interactions
lead to deletion, Vk1 and non-Vk1 anti-dsDNA antibodies
demonstrate similar affinities for dsDNA. The difference in
regulation, therefore, does not appear to be due to a differ-
ence in affinity for dsDNA. Nor does the difference in reg-
ulation correlate with differences in the pathogenic potential
of these antibodies. Cell lines secreting a Vk1 and non-Vk1
anti-dsDNA antibody were injected into SCID mice and
both antibodies deposited in glomeruli.
The relative contribution of kappa light chains in DNA
specificity have previously been reported (30, 31). Radic et al.
have demonstrated that the pairing of the 3H9 anti-DNA
heavy chain with different light chains alters the ability of
the antibody to bind dsDNA, cardiolipin, and RNA, al-
though all antibodies retain the ability to bind ssDNA (31).
More recently, Retter et al. has suggested that the light
chain may confer upon the antibody a second cross-reac-
tive specificity (32). We propose that perhaps it is on the
basis of a second light chain–associated specificity that B cells
producing R4A anti-dsDNA antibodies are either deleted
or silenced. To begin to test this hypothesis, we measured
binding of hybridoma antibodies to ssDNA. Although we
have identified a few antibodies that bind strongly to ssDNA,
we have not observed any trend that might explain the dif-
ferential regulation of Vk1 and non-Vk1 antibodies. In fact,
two of these antibodies use non-Vk1 genes and appear to
be deleted from the nonautoimmune mice rather than an-
ergized as one might expect.
The simplest interpretation of our studies is that DNA is
not the critical antigen mediating selection of these autore-
active B cells. There is increasing evidence that anti-DNA
antibodies can cross-react with several other self antigens
including fibronectin, laminin, heparan sulfate, collagen, and
cardiolipin, as well as nuclear antigens (33–37). If dsDNA were
the critical selecting antigen and receptor occupancy alone
determined cell fate, then both Vk1 and non-Vk1 B cells
would undergo the same form of negative selection. Just as
recent data raise the possibility that anti-DNA antibodies
may mediate tissue injury by binding cross-reactive antigens,
anti-DNA B cells may be regulated by cross-reactive anti-
gens.
This transgenic model provides a unique opportunity to
study the molecular basis for differential regulation of au-
toreactive B cells, and suggests that affinity for dsDNA is
not the critical determinant of the fate of anti-dsDNA B
cells. If dsDNA is indeed a self antigen capable of mediating
negative selection, our data suggest that antigen binding on
the membrane of a B cell may engage the B cell receptor
complex to either delete or inactivate autoreactive B cells
depending on properties not correlated with affinity for an-
tigen. More likely, different light chains associating with
the R4A heavy chain mediate binding to cross-reactive an-
tigens and this cross-reactivity plays a role in determining
the fate of the autoreactive anti-dsDNA B cells. The iden-
tity of these putative cross-reactive antigens remains to be
determined in future studies.
Table 2. Affinity Measurements of Anti-dsDNA Antibodies
Cell line Affinity constants Vk family
aKa*
B12CB-1 6.60 3 108 Vk1
BA129B-1 1.10 3 109 Vk1
NZW5G3 1.1 3 109 Vk1
NZW14E10 1.65 3 109 Vk1
NZW2C8 1.32 3 109 Vk1
BW10D9 5.08 3 108 Vk1
BW7F5 1.76 3 109 Vk10
BW16B2 6.60 3 108 Vk10
BW14C7B1 1.32 3 109 Vk4/5
BW9B5F7 5.29 3 109 Vk2
*Apparent affinity constants (aKa) measured by inhibition ELISA ac-
cording to Nieto et al. (20). Data shown are representative of a mini-
mum of two assays done in triplicate.
Table 3. Cross-reactivity with ssDNA
Cell lines OD 405 nm
BA129B-1 2.468 6 0.203
BA126E-2 0.303 6 0.051
BW14C7B1 2.768 6 0.119
BW9B5F7 2.202 6 0.101
BW15D6F2 0.286 6 0.044
R4A 0.159 6 0.013
ELISA measurements of anti-dsDNA antibodies that cross-react with
ssDNA. Results are the average of triplicates 6 standard deviation.1325 Spatz et al.
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